Preformed cytotoxic antibody in patients subjected to thoracic duct drainage.
1. Patients subjected to TDD prior to transplantation had a 4-yr graft survival rate of 65% compared to a comparably HL-A-matched group in which the survival rate was 35%9 2. Patients classified as non-responders to tissue antigens have a much higher graft retention rate than responders. Responders subjected to TDD have a 1 yr graft survival rate of 62% compared to a comparably HL-A-matched group with a survival rate of 28%. 3. Individuals with a positive crossmatch or receiving second or third transplants and subjected to TDD do much better than such individuals not subjected to TDD.
D003601:Cytotoxicity Tests, Immunologic; D004322:Drainage; D005260:Female; D006084:Graft Rejection; D006649:Histocompatibility Antigens; D006801:Humans; D007165:Immunosuppression Therapy; D007518:Isoantibodies; D016030:Kidney Transplantation; D008297:Male; D013897:Thoracic Duct / Q000276:immunology*; D014184:Transplantation, Homologous
D006649:Histocompatibility Antigens; D007518:Isoantibodies